{
    "clinical_study": {
        "@rank": "6420", 
        "arm_group": [
            {
                "arm_group_label": "Sitagliptin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose\n      concentrations in Type I Diabetic subjects.  The study also aims to evaluate post meal\n      glucagon concentrations in Type I Diabetic subjects (a possible mechanism of reduced blood\n      glucose concentrations) and indices of oxidation stress in the plasma of these subjects."
        }, 
        "brief_title": "Sitagliptin in Type I Diabetic Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Type I", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 1"
        }, 
        "detailed_description": {
            "textblock": "The hypothesis is that Sitagliptin will improve overall blood glucose, fasting blood\n      glucose, and glycemic excursions in patients with Type I Diabetes.  In addition, sitagliptin\n      will likely suppress indices of oxidative stress in patients.  The study will investigate\n      proposed mechanisms of improved glucose concentrations, including enhanced effect of\n      endogenous GLP-1 and suppression of glucagon."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female adult, aged 18 to 70 years\n\n          2. Type 1 Diabetes Mellitus for 6 months or more, as established by medical history\n\n          3. Current treatment with multiple injections of insulin (at least 4) or CSII\n             (continuous subcutaneous insulin infusion or insulin pump) therapy for at least 3\n             months prior to screening visit; and using the same insulin during the last 1 month\n\n          4. HbA1c \u2264 8.5%\n\n          5. Subjects should routinely practice at least 2-4 blood glucose measurements per day\n\n          6. BMI \u2264 35 kg/m2\n\n          7. Subject must be able and willing to perform self-blood glucose monitoring and accept\n             wearing a continuous glucose monitor for 3 days at the start and 3 days at the end of\n             the study\n\n          8. Subjects must be willing to complete study visits per study protocol\n\n          9. Able to speak, read, and write English\n\n        Exclusion Criteria:\n\n          1. Type 1 Diabetes Mellitus for less than 6 months\n\n          2. Coronary Event or procedure (myocardial infarction, unstable angina, coronary artery\n             bypass surgery, or coronary angioplasty) in the previous 4 weeks\n\n          3. Any other life-threatening, non-cardiac disease\n\n          4. Pregnant or intends to become pregnant during the course of the study\n\n          5. Severe unexplained hypoglycemia that required emergency treatment over the past 3\n             months\n\n          6. History of hemoglobinopathies\n\n          7. Post-renal transplantation, currently undergoing dialysis, creatinine of >1.5mg/dl or\n             a calculated creatinine clearance of <50 mL/min.\n\n          8. Have extensive skin changes/diseases that inhibit wearing the sensor on normal skin\n\n          9. Subjects who have an allergy to medication being used\n\n         10. Current participation in another study protocol\n\n         11. History of autonomic neuropathy or gastroparesis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741103", 
            "org_study_id": "1957"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin", 
                "description": "sitagliptin 100mg by mouth once a day for 12 weeks", 
                "intervention_name": "sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Januvia/Sitagliptin 100mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Take one by mouth daily for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 30, 2012", 
        "location": {
            "contact": {
                "email": "pdandona@kaleidahealth.org", 
                "last_name": "Paresh Dandona, MD", 
                "phone": "716-626-7998"
            }, 
            "facility": {
                "address": {
                    "city": "Williamsville", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14221"
                }, 
                "name": "115 Flint Road"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Sitagliptin on Glycemic Control, Post-prandial Glucagon, and Inflammation in Type 1 Diabetics", 
        "overall_contact": {
            "email": "pdandona@kaleidahealth.org", 
            "last_name": "Paresh Dandona, MD", 
            "phone": "716-887-4069"
        }, 
        "overall_official": {
            "affiliation": "Kaleida Health and University at Buffalo", 
            "last_name": "Paresh Dandona, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is to detect the change from baseline in mean glucose concentrations as measured by both HbA1c, and mean glucose over the three days of continuous glucose monitoring.", 
            "measure": "change from baseline in mean glucose concentrations", 
            "safety_issue": "No", 
            "time_frame": "baseline and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741103"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaleida Health", 
            "investigator_full_name": "Paresh Dandona, MD", 
            "investigator_title": "Clinical Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Glycemic changes including standard deviations of the glycemic levels, fructosamine, and the duration of time spent in hyperglycemia and hypoglycemia.", 
                "measure": "Glycemic changes", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 months"
            }, 
            {
                "description": "Post meal hyperglycemia will be measured as area under the curve (AUC).", 
                "measure": "Post meal hyperglycemia", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 months"
            }, 
            {
                "measure": "Changes in post prandial glucose, glucagon, insulin, c-peptide, DPP-IV, GIP and, GLP-1 concentrations following meal challenge.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 months"
            }, 
            {
                "measure": "Changes  in NF kappa B in the fasting state.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 months"
            }, 
            {
                "measure": "Change in NFkappaB following meal challenge.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 Months"
            }
        ], 
        "source": "Kaleida Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaleida Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }
}